Calliditas Q1 report, January – March 2024
Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX): Target market expansion following full approval in the USJANUARY – MARCH 2024 (COMPARED TO JANUARY – MARCH 2023) · Net sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net sales amounted to SEK 191.4 million, of which TARPEYO net sales amounted to SEK 185.7 million. · Operating loss amounted to SEK 203.8 million and SEK 180.1 million for the three months ended March 31, 2024, and 2023,